Scott A Mosley, Emily Cicali, Alex Del Cueto, Diane G Portman, Kristine A Donovan, Yan Gong, Taimour Langaee, Priya Gopalan, Jessica Schmit, Jason S Starr, Natalie Silver, Young D Chang, Sahana Rajasekhara, Joshua E Smith, Heloisa P Soares, Mike Clare-Salzler, Petr Starostik, Thomas J George, Howard L McLeod, Roger B Fillingim, J Kevin Hicks, Larisa H Cavallari
INTRODUCTION: The CYP2D6 enzyme metabolizes opioids commonly prescribed for cancer-related pain, and CYP2D6 polymorphisms may contribute to variability in opioid response. We evaluated the feasibility of implementing CYP2D6-guided opioid prescribing for patients with cancer and report pilot outcome data. METHODS: Adult patients from two cancer centers were prospectively enrolled into a hybrid implementation-effectiveness clinical trial and randomized to CYP2D6-genotype guided opioid selection, with clinical recommendations, or usual care...
September 12, 2023: Pharmacotherapy